U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H53N2O4
Molecular Weight 529.7754
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of ROCURONIUM

SMILES

C=CC[N+]1(CCCC1)[C@@]2([H])C[C@@]3([H])[C@]4([H])CC[C@@]5([H])C[C@@]([H])([C@]([H])(C[C@]5(C)[C@@]4([H])CC[C@]3(C)[C@@]2([H])OC(=O)C)N6CCOCC6)O

InChI

InChIKey=YXRDKMPIGHSVRX-OOJCLDBCSA-N
InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H52N2O4
Molecular Weight 528.7675
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including http://reference.medscape.com/drug/zemuron-rocuronium-343109 | https://www.drugs.com/pro/rocuronium-bromide-injection.html | https://www.drugbank.ca/drugs/DB00728 | https://www.ncbi.nlm.nih.gov/pubmed/2573387 | https://www.ncbi.nlm.nih.gov/pubmed/21568994

Rocuronium (brand names Zemuron, Esmeron) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anesthesia to facilitate endotracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Most common adverse reactions are transient hypotension and hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZEMURON

Approved Use

Rocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. (1)

Launch Date

7.6386238E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
0.6 mg/kg single, intravenous
dose: 0.6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.9 h
0.45 mg/kg single, intravenous
dose: 0.45 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
0.6 mg/kg single, intravenous
dose: 0.6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (14%)
Vomiting (3%)
Sources:
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (14%)
Vomiting (6%)
Procedural hypotension (5%)
Sources:
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (17%)
Vomiting (8%)
Procedural hypotension (5%)
Nausea (5%)
Sources:
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (18%)
Vomiting (12%)
Procedural hypotension (4%)
Nausea (4%)
Sources:
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Other AEs: Procedural pain, Hypercapnia...
Other AEs:
Procedural pain (12%)
Hypercapnia (3%)
Nausea (3%)
Sources:
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
midazolam(1-2 mg)
propofol(1.8 mg/kg)
alfentanil(9 ug/kg)
Sources:
unhealthy, 33.1
n = 20
Health Status: unhealthy
Condition: surgical procedures
Age Group: 33.1
Sex: F
Population Size: 20
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Procedural pain 14%
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Vomiting 3%
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Procedural pain 14%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Procedural hypotension 5%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Vomiting 6%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Procedural pain 17%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Nausea 5%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Procedural hypotension 5%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Vomiting 8%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Vomiting 12%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural pain 18%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Nausea 4%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural hypotension 4%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural pain 12%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Hypercapnia 3%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Nausea 3%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Nausea and vomiting 2 patients
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
midazolam(1-2 mg)
propofol(1.8 mg/kg)
alfentanil(9 ug/kg)
Sources:
unhealthy, 33.1
n = 20
Health Status: unhealthy
Condition: surgical procedures
Age Group: 33.1
Sex: F
Population Size: 20
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes
PubMed

PubMed

TitleDatePubMed
Effects of pretreatment with cisatracurium, rocuronium, and d-tubocurarine on succinylcholine-induced fasciculations and myalgia: a comparison with placebo.
1999 Dec
Choice of the muscle relaxant for rapid-sequence induction.
2001
Recovery of neuromuscular block in morbidly obese patients following an infusion of rocuronium.
2001
Target controlled infusion of remifentanil and propofol for cesarean section in a patient with multivalvular disease and severe pulmonary hypertension.
2001
Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery.
2001
[Rocuronium or vecuronium for intubation for short operations in the preschool age? Effects on time in the operating room and postoperative phase].
2001
Newer neuromuscular blocking agents: how do they compare with established agents?
2001
[Total intravenous anesthesia using remifentanil and propofol with midazolam co-induction in laparoscopic surgery of the gallbladder].
2001
Anesthesia for Cesarean section and posterior fossa craniotomy in a patient with von Hippel-Lindau disease.
2001 Apr
Neostigmine antagonism of rocuronium block during anesthesia with sevoflurane, isoflurane or propofol.
2001 Apr
Rocuronium-induced neuromuscular blockade is affected by chronic phenytoin therapy.
2001 Apr
Postoperative residual block after intermediate-acting neuromuscular blocking drugs.
2001 Apr
Safety and efficacy of rocuronium for controlled intubation with paralytics in the pediatric emergency department.
2001 Aug
The pharmacoeconomics of neuromuscular blocking drugs: a perioperative cost-minimization strategy in children.
2001 Aug
The new neuromuscular blocking agents: do they offer any advantages?
2001 Dec
[New muscle relaxants].
2001 Dec
Why do we still use suxamethonium for caesarean section?
2001 Dec
Equi-lasting doses of rocuronium, compared to mivacurium, result in improved neuromuscular blockade in patients undergoing gynecological laparoscopy : [Des doses de durée équivalente de rocuronium, comparé au mivacurium, améliorent la curarisation chez des patientes qui subissent une laparoscopie gynécologique].
2001 Dec
[Sevoflurane augments the degree and speeds the onset of rocuronium evoked neuromuscular blockade in children].
2001 Dec
Reversal of rocuronium with edrophonium during propofol versus sevoflurane anesthesia.
2001 Feb
Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients.
2001 Jan
The influence of halothane, isoflurane and sevoflurane on rocuronium infusion in children.
2001 Jan
No substitute for the intravenous route.
2001 Jan
The effects of remifentanil on haemodynamic stability during rigid bronchoscopy.
2001 Jun
Rocuronium: high risk for anaphylaxis?
2001 May
Onset and duration of action of rocuronium--from tracheal intubation, through intense block to complete recovery.
2001 May
Rocuronium and anaphylaxis--a statistical challenge.
2001 Nov
Rapid sequence induction: a national survey of practice.
2001 Nov
Is succinylcholine appropriate or obsolete in the intensive care unit?
2001 Oct
Huntington's chorea: use of rocuronium.
2001 Oct
Reexamined: the recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset.
2001 Oct
Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison between female and male patients.
2001 Sep
Incidence of UK reactions involving rocuronium may simply reflect market use.
2001 Sep
Effect of ondansetron pretreatment on pain after rocuronium and propofol injection: a randomised, double-blind controlled comparison with lidocaine.
2001 Sep
An isolated, antegrade, perfused, peroneal nerve anterior tibialis muscle model in the rat: a novel model developed to study the factors governing the time course of action of neuromuscular blocking agents.
2002 Apr
Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action.
2002 Apr
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.
2002 Apr 25
Comparison of rocuronium and suxamethonium for rapid tracheal intubation in children.
2002 Feb
Prehospital tracheal intubating conditions during rapid sequence intubation: rocuronium versus vecuronium.
2002 Jan-Feb
2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide.
2002 Jun
Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly.
2002 Mar
The influence of induction technique on intubating conditions 1 min after rocuronium administration: a comparison of a propofol-ephedrine combination and propofol.
2002 Mar
The neuropathologic effects in rats and neurometabolic effects in humans of large-dose remifentanil.
2002 May
Patents

Sample Use Guides

0.45-0.6 mg/kg IV Maintenance: 0.1-0.2 mg/kg IV repeat PRN OR Continuous infusion: 0.01-0.012 mg/kg/min IV
Route of Administration: Intravenous
Aliquots of 100 mkl whole heparinized blood of rocuronium-allergic patients (positive basophil activation test and skin test) were challenged at 37 C with buffer as a negative control, anti-IgE (Pharmingen,BDBioscience, Erembodegem, Belgium) as a positive control, serial dilutions of rocuronium (Esmeron, Organon, Brussels, Belgium, 0.2–2.0 x 10^3 mkg/ml), serial dilutions of sugammadex (Bridion; Merck Sharp & Dohme, Oss, The Netherlands) 0.2–2.0 x 10^3 mkg/ml and with a mixture of different concentrations of rocuronium and sugammadex. Flow cytometric analysis of basophils was performed using triple labelling with CD123-PE, HLA-DR-PerCP, CD63-FITC (BD Biosciences) and using monoclonal antihuman IgE (clone GE-1; Sigma-Aldrich Chemic GmBH, Steinheim, Germany), labelled with AlexaFluor 488 (Molecular Probes, Invitrogen, Paisley, UK). Samples were analysed on a flow cytometer (FACsCanto BD; Immunocytometry Systems, San Jose, CA, USA) and expressed as CD63-positive basophils. Samples were regarded as positive when CD63-reactive basophils were higher than 4%
Substance Class Chemical
Created
by admin
on Fri Jun 25 23:07:23 UTC 2021
Edited
by admin
on Fri Jun 25 23:07:23 UTC 2021
Record UNII
WRE554RFEZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROCURONIUM
MI   WHO-DD  
Common Name English
ROCURONIUM ION
Common Name English
ROCURONIUM [WHO-DD]
Common Name English
ROCURONIUM [MI]
Common Name English
PYRROLIDINIUM, 1-((2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)-17-(ACETYLOXY)-3-HYDROXY-2-(4-MORPHOLINYL)ANDROSTAN-16-YL)-1-(2-PROPENYL)-
Systematic Name English
ROCURONIUM CATION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66886
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
NDF-RT N0000175732
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
NDF-RT N0000175720
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
WHO-ATC M03AC09
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C80999
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
PUBCHEM
441290
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
LACTMED
Rocuronium
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
DRUG BANK
DB00728
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
RXCUI
68139
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
Rocuronium
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
DRUG CENTRAL
2396
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
EVMPD
SUB04260MIG
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
MESH
C061870
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
CAS
143558-00-3
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
MERCK INDEX
M9645
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY Merck Index
IUPHAR
4003
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
EPA CompTox
143558-00-3
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
FDA UNII
WRE554RFEZ
Created by admin on Fri Jun 25 23:07:23 UTC 2021 , Edited by admin on Fri Jun 25 23:07:23 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
17-desacetyl-rocuronium has been found in negligible amounts
MINOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC